Lasa Supergenerics Limited Stock Price Today (NSE: LASA)
Fundamental Score
Lasa Supergenerics Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Lasa Supergenerics Limited share price today is ₹6.20, up +0.00% on NSE/BSE as of 16 September 2026. Lasa Supergenerics Limited (LASA) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹31.06 (Cr). The 52-week high for LASA share price is ₹14.08 and the 52-week low is ₹5.67. The company has a Return on Equity (ROE) of -51.13% and a debt-to-equity ratio of 0.20.
Lasa Supergenerics Limited Share Price Chart — NSE/BSE Historical Performance
Lasa Supergenerics Limited share price chart: -13.12% return over the past month. 52-week high ₹14.08, 52-week low ₹5.67.
Lasa Supergenerics Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹6.20 | ₹6.20 | ₹6.20 | ₹6.20 | 18.31K (Cr) | |
| ₹6.71 | ₹6.71 | ₹6.45 | ₹6.52 | 46.91K (Cr) | |
| ₹6.70 | ₹6.83 | ₹6.65 | ₹6.69 | 35.67K (Cr) | |
| ₹6.73 | ₹6.80 | ₹6.60 | ₹6.68 | 17.59K (Cr) | |
| ₹6.99 | ₹7.00 | ₹6.69 | ₹6.73 | 24.57K (Cr) | |
| ₹6.90 | ₹6.98 | ₹6.81 | ₹6.82 | 25.65K (Cr) | |
| ₹6.96 | ₹6.96 | ₹6.66 | ₹6.78 | 20.79K (Cr) | |
| ₹6.92 | ₹7.04 | ₹6.70 | ₹6.76 | 27.18K (Cr) | |
| ₹7.10 | ₹7.28 | ₹6.73 | ₹6.92 | 36.81K (Cr) | |
| ₹7.00 | ₹7.42 | ₹6.85 | ₹6.99 | 69.59K (Cr) |
Lasa Supergenerics Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹6.92 | ₹7.04 | ₹6.20 | ₹6.20 | -10.40% | |
| ₹7.10 | ₹8.45 | ₹6.42 | ₹6.92 | -2.54% | |
| ₹7.59 | ₹7.90 | ₹6.66 | ₹6.87 | -9.49% | |
| ₹8.35 | ₹8.35 | ₹6.76 | ₹7.56 | -9.46% | |
| ₹7.98 | ₹8.77 | ₹7.55 | ₹8.31 | +4.14% | |
| ₹5.67 | ₹9.00 | ₹5.67 | ₹8.00 | +41.09% | |
| ₹7.36 | ₹8.30 | ₹5.67 | ₹5.67 | -22.96% | |
| ₹9.30 | ₹9.45 | ₹7.66 | ₹7.98 | -14.19% | |
| ₹10.38 | ₹12.48 | ₹8.72 | ₹9.39 | -9.54% | |
| ₹9.54 | ₹10.28 | ₹8.51 | ₹9.44 | -1.05% | |
| ₹11.60 | ₹11.95 | ₹9.01 | ₹9.55 | -17.67% | |
| ₹11.50 | ₹12.20 | ₹9.81 | ₹11.60 | +0.87% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Lasa Supergenerics Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Lasa Supergenerics Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of LASA across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Conservative Debt Levels (D/E: 0.20)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Healthy Liquidity Position (Current Ratio: 1.90)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Balanced Promoter Holding (53.65%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Risk Factors
10 factors identified
Below-Average Return on Equity (-51.13%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-28.80%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-25.55%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Profit Decline Concern (-83.05%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-93.87%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (-34.11% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Interest Coverage (-88.61x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-33.57 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
High Share Pledging Risk (20.66%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Lasa Supergenerics Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Lasa Supergenerics Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
0/100 | ₹6.20₹6 | ₹31.06₹31.06 | — — | -51.13%Poor -51.13% Poor | -28.80%Poor -28.80% Poor | 0.20Excellent 0.2 Excellent | — — | -34.11%Poor -34.11% Poor | 0.00% | |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9443.00₹9443 | ₹250239.50₹250239.50 | 85.68Average 85.7 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1370.20₹1370 | ₹110691.61₹110691.61 | 32.83Average 32.8 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1672.10₹1672 | ₹96212.63₹96212.63 | 26.13Average 26.1 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.80₹1146 | ₹95674.30₹95674.30 | 29.61Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price250239.50 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110691.61 Cr
Lasa Supergenerics Limited Quarterly Performance
Latest quarterly metrics for LASA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-93.87%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-83.05%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-34.11%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Lasa Supergenerics Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for LASA — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Lasa Supergenerics Limited Financial Statements
Annual income statement, balance sheet and cash flow for Lasa Supergenerics Limited (LASA) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Lasa Supergenerics Limited
About LASA (Lasa Supergenerics Limited)
Lassonde Industries Inc. is a multifaceted North American leader renowned for its diverse portfolio of high-quality food and beverage products. While not directly operating within ...the pharmaceutical sector, Lassonde's focus on wellness and nutrition resonates deeply with the principles underlying the health and pharmaceutical industries. The company meticulously sources ingredients and employs advanced processing techniques to ensure the integrity and nutritional value of its products, a commitment that mirrors the rigorous standards applied in pharmaceutical manufacturing. Lassonde's extensive research and development efforts are dedicated to creating innovative products that cater to evolving consumer needs and preferences, reflecting a similar drive for innovation found in pharmaceutical research aimed at developing new and improved treatments. Lassonde's expertise in the food and beverage industry translates into a deep understanding of consumer health trends and dietary requirements. This knowledge base allows the company to formulate products that promote overall well-being and support specific health goals. Their range of fruit juices, vegetable juices, smoothies, and plant-based beverages demonstrates a commitment to providing consumers with convenient and nutritious options. This focus on preventative health and wellness, through carefully crafted food and beverage offerings, aligns with the broader healthcare landscape, contributing to a more health-conscious society. The company's dedication to quality and safety further reinforces its commitment to consumer well-being. Lassonde Industries Inc. operates with a strong sense of corporate social responsibility, prioritizing sustainable practices and ethical sourcing. This commitment extends to its supply chain, ensuring that ingredients are obtained responsibly and with minimal environmental impact. Lassonde's dedication to transparency and traceability in its operations builds trust with consumers and stakeholders alike. While not a pharmaceutical company, Lassonde's dedication to ethical practices, consumer health, and innovative product development mirrors the core values of the healthcare industry and demonstrates a clear commitment to enhancing the overall well-being of its consumers.
Company Details
Key Leadership
LASA Share Price: Frequently Asked Questions
What is the current share price of Lasa Supergenerics Limited?
Lasa Supergenerics Limited (LASA) trades at ₹6.20 on NSE and BSE. Market cap ₹31.06 (Cr). Educational data only.
What is the P/E ratio of Lasa Supergenerics Limited?
Lasa Supergenerics Limited has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Lasa Supergenerics Limited?
Lasa Supergenerics Limited has a Bull Run score of 0/100 based on 25+ financial parameters.
Does Lasa Supergenerics Limited pay dividends?
Lasa Supergenerics Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Lasa Supergenerics Limited?
Lasa Supergenerics Limited has ROE of -51.13%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Lasa Supergenerics Limited?
Lasa Supergenerics Limited has debt-to-equity of 0.20.
Is Lasa Supergenerics Limited a good investment?
Bull Run gives Lasa Supergenerics Limited a score of 0/100. This is not investment advice — consult a SEBI-registered advisor.